NASDAQ (usa) arrow 6715.56 -12.11 -0.18%
FTSE 100 (london) arrow 7487.96 -5.12 -0.07%
DAX (german) arrow 13465.51 235.94 1.78%
NIKKEI 225 (japan) arrow 22420.08 408.47 1.86%
Hang - Seng (hong kong) arrow 28594.06 348.52 1.23%
NIFTY - 50 (india)
Straits Times (singapore) arrow 3391.61 17.53 0.52%
KOSPI (korea) arrow 2556.47 33.04 1.31%
All Ordinaries (australia) arrow 6005.30 28.90 0.48%
BOVESPA (brazil) arrow 74092.76 -215.73 -0.29%

Acer Therapeutics Inc (NASDAQ: ACER)

 
ACER Technical Analysis
1
As on 14th Aug 2024 ACER SHARE Price closed @ 0.90 and we RECOMMEND N/A for LONG-TERM with Stoploss of 0.00 & N/A for SHORT-TERM with Stoploss of 0.00 we also expect STOCK to react on Following IMPORTANT LEVELS.
 
 

ACERSHARE Price

Open 0.90 Change Price %
High 0.90 1 Day N/A N/A
Low 0.90 1 Week 0.00 0.00
Close 0.90 1 Month 0.00 0.00
Volume N/A 1 Year 0.00 0.00
52 Week High 0.00 | 52 Week Low 0.00
 
NASDAQ USA Most Active Stocks
AMRS 0.14 100.00%
GNLN 0.01 -50.00%
AGMH 0.05 25.00%
OMEX 1.51 77.65%
NVDA 111.01 4.30%
WW 0.40 166.67%
TSLA 284.95 9.80%
INTC 20.05 -6.70%
OPEN 0.76 -2.56%
LMDX 0.02 0.00%
 
NASDAQ USA Top Gainers Stocks
KTRA 6.30 2763.64%
ZWZZT 25.00 2375.25%
IDRA 8.64 1909.30%
REDU 3.41 1075.86%
CTXRW 0.14 600.00%
NDRAW 0.03 200.00%
WW 0.40 166.67%
WINVR 0.12 140.00%
GLSPT 33.43 138.62%
BIOC 0.07 133.33%
 
NASDAQ USA Top Losers Stocks
OTIC 0.01 -91.67%
PTRAW 0.23 -89.59%
ACAQ-UN 2.50 -73.49%
AGBA 0.35 -71.31%
AXAS 0.03 -70.00%
BPTH 0.21 -66.67%
TFFP 0.06 -62.50%
ATMH 0.04 -60.00%
MILEW 0.06 -53.85%
LOTZW 0.01 -50.00%
 
 
ACER
Daily Charts
ACER
Intraday Charts
Whats New @
Bazaartrend
ACER
Free Analysis
 
ACER Important Levels Intraday
SUPPORT0.00
SUPPORT0.00
SUPPORT0.00
SUPPORT0.00
SUPPORT0.00
SUPPORT0.00
SUPPORT0.00
SUPPORT0.00
 
ACER Forecast April 2025
4th UP Forecast0
3rd UP Forecast0
2nd UP Forecast0
1st UP Forecast0
1st DOWN Forecast0
2nd DOWN Forecast0
3rd DOWN Forecast0
4th DOWN Forecast0
 
ACER Weekly Forecast
4th UP Forecast0.00
3rd UP Forecast0.00
2nd UP Forecast0.00
1st UP Forecast0.00
1st DOWN Forecast0.00
2nd DOWN Forecast0.00
3rd DOWN Forecast0.00
4th DOWN Forecast0.00
 
ACER Forecast2025
4th UP Forecast0
3rd UP Forecast0
2nd UP Forecast0
1st UP Forecast0
1st DOWN Forecast0
2nd DOWN Forecast0
3rd DOWN Forecast0
4th DOWN Forecast0
 
 
ACER Other Details
Segment EQ
Market Capital 33628968.00
Sector Healthcare
Industry Biotechnology
Offical website >
 
ACER Address
ACER
 
ACER Latest News
 
Your Comments and Response on Acer Therapeutics Inc
 
ACER Business Profile
Acer Therapeutics Inc., a pharmaceutical company, focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases. Its pipeline includes four clinical-stage candidates: EDSIVO for the treatment of vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mutation; ACER-001, a formulation of sodium phenylbutyrate for the treatment of various inborn errors of metabolism, including urea cycle disorders and maple syrup urine disease; ACER-801 (osanetant) for the treatment of induced Vasomotor Symptoms; and ACER-2820 (emetine), a host-directed therapy against a variety of infectious diseases, including COVID-19. The company has a research collaboration agreement with the National Center for Advancing Translational Sciences (NCATS) to develop emetine hydrochloride as a potential treatment for patients with COVID-19; and a license agreement with Sanofi to acquire worldwide rights to osanetant, a clinical-stage, selective, and non-peptide tachykinin NK3 receptor antagonist. Acer Therapeutics Inc. was founded in 1991 and is headquartered in Newton, Massachusetts. Address: One Gateway Center, Newton, MA, United States, 02458
 
© 2005-2023 BazaarTrend.com All rights reserved.

Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service